Design, Synthesis, and Anticancer Activity of N‐1 Terminal Segment of α‐(2, 5,7‐Tri‐tert‐butylindol‐3‐yl)alanine‐Incorporated Short Peptides

Abstract

AbstractUsing a minimallised approach,we designed and synthesized N‐terminal modified peptides W‐KRGNKWLA‐CONH2 (P1) and W‐ARGDGGNGRGA‐CONH2 (P2) using Fmoc‐Chemistry solid phase peptide synthesis protocol. High‐performance liquid chromatograms and mass spectrometry (LCMS and analytical HPLC) were employed to determine the purity and molecular weight of the peptide. Surface tension measurements are used to evaluate peptide surface activity. The primary structure of the peptideis anlaysed by NMR spectroscopy. Circular dichroism studies demonstrate that the secondary structure of the peptide changes minimally when it attached to anionic lipid bilayers (POPC : POPG). According to a steady‐state fluorescence experiment, peptides P1 and P2 preferentially interact with anionic (POPC : POPG) lipid bilayers rather than zwitterionic (POPC) lipid bilayers. The peptide P2 interacts preferentially with anionic lipid membranes and has an anticancer effect due to RGD and NGR binding motifs. The cytotoxicity of the MTT experiment demonstrated that both normal and cancerous cells could lower peptide concentrations below their IC50 levels. Molecular docking also supports in‐vitro anticancer research. Both peptides P1 and P2 were non‐toxic to vero cells and appeared to be more promising as it demonstrated wide spectrum anticancer activity.